Clostridioides difficile infection: a changing treatment paradigm

Yousif Al Naser; Marriam AlGashami; Layth Aljashaami

doi:10.5114/pg.2024.136237

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

1/2024
vol. 19

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Artykuł przeglądowy

Clostridioides difficile infection: a changing treatment paradigm

Yousif Al Naser

¹

,

Marriam AlGashami

²

,

Layth Aljashaami

³

McMaster University, Hamilton, ON, Canada

Royale College of Surgeons in Ireland, Dublin, Ireland

University of Arizona College of Medicine, Pheonix, AZ, USA

Gastroenterology Rev 2024; 19 (1): 1–5

DOI: https://doi.org/10.5114/pg.2024.136237

Data publikacji online: 2024/03/11

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Clostridioides difficile infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug developments that have the potential to reshape CDI treatment paradigms. Within the current treatment landscape, fidaxomicin, vancomycin, bezlotoxumab, and faecal microbiota transplantation offer varied options, each with its unique strengths and limitations. Fidaxomicin, effective yet resource-constrained, presents a dilemma, with vancomycin emerging as a pragmatic alternative. Bezlotoxumab, though augmenting antibiotics, grapples with cost and safety concerns. Meanwhile, faecal microbiota transplantation, highly efficacious, confronts evolving safety considerations. The horizon of CDI treatment also features promising therapies such as SER-109 and Rebyota, epitomising the evolving paradigm. As CDI management advances, the critical role of standardised microbiome restoration therapies becomes evident, ensuring long-term safety and diversifying treatment strategies.

Clostridioides difficile infection: a changing treatment paradigm

Yousif Al Naser 1 , Marriam AlGashami 2 , Layth Aljashaami 3

Yousif Al Naser

¹

,

Marriam AlGashami

²

,

Layth Aljashaami

³